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ABSTRACT
Guinea pig cytomegalovirus (GPCMV) provides a valuable model for congenital cytomegalovirus transmission. Salivary gland
(SG)-passaged stocks of GPCMV are pathogenic, while tissue culture (TC) passage in fibroblasts results in attenuation. Non-
pathogenic TC-derived virus N13R10 (cloned as a bacterial artificial chromosome [BAC]) has a 4-bp deletion that disrupts
GP129, which encodes a subunit of the GPCMV pentameric complex (PC) believed to govern viral entry into select cell types, and
GP130, an overlapping open reading frame (ORF) of unknown function. To determine if this deletion contributes to attenuation
of N13R10, markerless gene transfer in Escherichia coliwas used to construct virus r129, a variant of N13R10 in which the 4-bp
deletion is repaired. Virions from r129 were found to contain GP129 as well as two other PC subunit proteins, GP131 and GP133,
whereas these three PC subunits were absent fromN13R10 virions. Replication of r129 in fibroblasts appeared unaltered com-
pared to that of N13R10. However, following experimental challenge of immunocompromised guinea pigs, r129 induced signifi-
cant weight loss, longer duration of viremia, and dramatically higher (up to 1.5 106-fold) viral loads in blood and end organs
compared to N13R10. In pregnant guinea pigs, challenge with doses of r129 virus of>5 106 PFU resulted in levels of maternal
viremia, congenital transmission, pup viral loads, intrauterine growth restriction, and pupmortality comparable to that induced
by pathogenic SG virus, although higher doses of r129 were required. These results suggest that theGP129-GP130mutation is a
significant contributor to attenuation of N13R10, likely by abrogating expression of a functional PC.
IMPORTANCE
Tissue culture adaptation of cytomegaloviruses rapidly selects for mutations, deletions, and rearrangements in the genome, par-
ticularly for viruses passaged in fibroblast cells. Some of these mutations are focused in the region of the genome encoding com-
ponents of the pentameric complex (PC), in particular homologs of human cytomegalovirus (HCMV) proteins UL128, UL130,
and UL131A. These mutations can attenuate the course of infection when the virus is reintroduced into animals for vaccine and
pathogenesis studies. This study demonstrates that a deletion that arose during the process of tissue culture passage can be re-
paired, with subsequent restoration of pathogenicity, using BAC-based mutagenesis. Restoration of pathogenicity by repair of a
frameshift mutation in GPCMV geneGP129 using this approach provides a valuable genetic platform for future studies using
the guinea pig model of congenital CMV infection.
Infection with human cytomegalovirus (HCMV) is a leadingcause of disability in newborns, and development of an effective
vaccine is a major public health priority (1, 2). Preclinical model-
ing of vaccines against congenital infectionmust rely on the study
of species-specific CMVs, since HCMVwill not infect nonhuman
cells (3, 4). The study of guinea pig cytomegalovirus (GPCMV) is
particularly valuable, since this virus will cross the placenta and
infect pups in utero, leading to congenital transmission (5). Thus,
the GPCMVmodel has been utilized to examine a variety of sub-
unit vaccine and antiviral therapy strategies relevant to human
health (6–8).
Prior studies reported the successful cloning of the genome of
a tissue culture-attenuated variant of GPCMV strain 22122 as a
bacterial artificial chromosome (BAC) designated N13R10 (9).
Although virus derived from N13R10 grows like wild-type
GPCMV in cell culture, it was highly attenuated in vivo compared
to pathogenic salivary gland (SG)-adapted virus. Similar work
from other groups had previously demonstrated that a GPCMV
lacking a 1.6-kb region of the viral genome was attenuated in vivo
(10). Attenuation of N13R10 was observed in studies in which a
high dose (108 PFU) was administered to young female guinea
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pigs. This dose of virus produced transient viremia and impaired
weight gain, but did not cause mortality (11). A dose of 5  105
PFU administered to pregnant animals caused congenital infec-
tions in 60% of live-born pups but relatively low (17%) pupmor-
tality (12). In contrast, challenge of pregnant guinea pigs with
substantially lower doses of virulent, SG-adapted virus is highly
pathogenic in vivo. A dose as low as 1.7 105 PFU results in 60%
dammortality, and a dose of as little as 3.5 103 PFU can produce
up to 80% pup mortality (13). Based on these comparisons to SG
virus, adult guinea pigs tolerate a 5,880-fold-higher dose of
N13R10 without significant illness or mortality, while a 140-fold-
higher dose of N13R10 during pregnancy produces lower rates of
fetal transmission and pup loss (11, 12). The molecular basis for
the attenuation of N13R10 is uncertain, but DNA sequence com-
parisons of the SG virus andN13R10 genomes identified only two
differences resulting in alteration of annotated protein coding se-
quences: (i) a 4-bp deletion that disrupts overlapping genesGP129
and GP130 and (ii) a missense mutation in GP130 3= of the 4-bp
deletion/frameshift (14, 15).
Work published by several investigators has elucidated that
GP129, GP131, and GP133 encode three subunits of a protein
complex analogous to the pentameric complex (PC) thatmediates
entry of HCMV into monocytes and epithelial/endothelial cells
(10, 16–18). Deletion of this locus or disruption of individual
genes in GPCMV has previously been hypothesized to contribute
to attenuation (10). The absence of other deletions or mutations
impacting annotated coding sequences in the N13R10 genome
(14) strengthened this hypothesis and prompted us to examine
whether loss ofGP129 accounted for attenuation ofN13R10 virus.
To test this hypothesis, we repaired the N13R10 GP129-GP130
region to match that of the SG stock of GPCMV and then evalu-
ated the mutant parental virus (N13R10) and repaired virus
(r129) for growth properties and gene expression in vitro and for
virulence in vivo. The r129 virus was strikingly more virulent than
N13R10, confirming that mutations impactingGP129 andGP130
contribute to the attenuation of N13R10. The increased pathoge-
nicity of r129, which can be manipulated using BAC genetics, will
greatly facilitate vaccine and pathogenesis studies in the GPCMV
model of congenital infection.
MATERIALS AND METHODS
Virus and cells. Cell culture propagation of virus was carried out in
guinea pig lung fibroblast cells (GPL cells [ATCC CCL158]) main-
tained in F-12 medium supplemented with 10% fetal calf serum (FCS
[Fisher Scientific]), 10,000 IU/liter penicillin, 10 mg/liter streptomycin
(Gibco-BRL), and 0.075% NaHCO3 (Gibco-BRL). Growth curves and
viral titers were determined as described previously (9).
Construction of N13R10-r129 BAC and reconstitution of viruses
N13R10 and r129. BAC N13R10 contains the complete GPCMV strain
22122 genome (9), with a deletion that disrupts open reading frames
(ORFs) GP129 and GP130. BAC N13R10-r129 was constructed using a
two-step galactokinase-mediated recombineering approach (19). In the
first step, nucleotides (nt) 205537 to 206226 of BACN13R10, comprising
exon 3 ofGP129, as annotated in GenBank accession no. KM384022 (14),
were deleted and subsequently replaced with a galK cassette encoding
galactokinase. To generate this deletion construct, oligonucleotides
GP129-galk-FW (CGCCGATTCTATCGCTTGCCTGCTAATAAATTG
GAACTGGACGTGATAAAACGACTCACTATAGGGCGAATTGG) and
GP129-galk-RV (TACTTCCCGTTACCATCGACTGAATAAAACTCGC
TACCGCAGACGTCCACGCTATGACCATGATTACGCCAAGC) were
synthesized to contain 50 bp of GPCMV sequences (underlined) flanking
the region to be deleted followed by 24-bp sequences complementary to
plasmid pgalK encoding the galK cassette (19). Using GP129-galk-FW
and GP129-galk-RV as primers and pgalK DNA as the template, a
1.5-kb PCR product was produced containing the galK cassette flanked
by 50-bp GPCMV targeting homologies. The product was purified using a
QiagenPCRpurificationkit, restrictedwithDpnI todigest any residual pgalK
DNA, and then phenol-chloroform extracted and ethanol precipitated.
Heat-induced electrocompetent Escherichia coli strain SW102 (9) cells
containing BAC N13R10 were produced as follows. Cells were incubated
with shaking at 32°C in LB containing 12.5 g/ml chloramphenicol until
an optical density at 600 nm (OD600) of 0.6 was reached. Tenmilliliters of
culture was then transferred to a 75-cm2 tissue culture flask and heat
induced by shaking at 42°C for exactly 15 min. The culture was chilled in
a water-ice slurry for 5 min and then pelleted at 5,000 rpm at 0°C for 5
min. Cells were washed twice with ice-cold water and resuspended in
ice-cold water to a final volume of 50 l.
Heat-induced electrocompetent cells were combined with 200 ng of
the PCR product described above, transferred to a prechilled 0.1-cm elec-
troporation cuvette (Bio-Rad), and electroporated at 1.8 kV with a Bio-
RadMicroPulser set to program EC1. Electroporated cells were diluted in
1 ml LB and incubated with shaking for 1.5 h at 32°C, then washed twice
in M9 salts, resuspended in 100 l M9 salts, spread on Gal-positive selec-
tion plates (19), and incubated at 32°C.
Colonies were screened by PCR using primer galk-test3 (GCTGTCG
TCATCATCAACAG) located within galK sequences and primer delt129-
galk down (GGTTATACGTGAACACGACG) located in GPCMV se-
quences adjacent to the inserted galK cassette. BAC DNAs from colonies
that produced the predicted 746-bp product were further analyzed by
HindIII digestion. A clone exhibiting a novel 5.1-kb HindIII fragment
relative to BACN13R10 (data not shown) consistent with insertion of the
galK cassette was selected and designated BAC N13R10-129-galk.
In the second step, selection against galactokinase was used to replace
the galK cassette with wild-type GP129 exon 3 sequences. PCR using
primers GP129-out FW (CTGACCAGCTTGAGAACGTA) and GP129-
out RV (ATTAAGCATGGGCGACATCC) was used to generate a 1.2-kb
product from DNA extracted from a pathogenic salivary gland stock of
GPCMV strain 22122 (20). The product was gel purified, and 200 ng was
electroporated into heat-induced electrocompetent E. coli strain SW102
cells containing BAC N13R10-129-galk as described above. After elec-
troporation, cells were diluted in 8 ml LB and incubated with shaking at
32°C for 4.5 h. One milliliter of culture was washed twice in M9 salts,
resuspended in 100 l M9 salts, and then spread on Gal counterselection
plates (19) and incubated at 32°C.
Colonies were screened by PCR using two primer pairs: (i) GP129
up-FW (CGGCGCTAAACTCTACGTTA) and GP129 mid-RV (TGTTG
CACGCGACGATCTTT) and (ii) GP129-mid FW (GACGCCACACTTT
CCGAGAG) and GP129-down-RV (ATCAAGAGACGTCCGGCGGA).
BAC DNAs from colonies that produced the predicted 584- and 746-bp
products, respectively, were further analyzed by HindIII digestion. A
clone exhibiting loss of the novel 5.1-kb fragment relative to BAC
N13R10-129-galk (data not shown), consistent with replacement of the
galK cassette with wild-type GP129 exon 3 sequences, was selected and
designated BACN13R10-r129. Direct Sanger sequencing ofN13R10-r129
BAC DNA confirmed that both the 4-bp deletion and the missense mu-
tation were repaired to match SG virus sequence. However, two appar-
ently spontaneous mutations were detected near the C-terminal end of
GP130 that resulted in R93Q and P97S substitutions in the predicted
amino acid sequence of GP130. As thesemutations were within the intron
between exons 1 and 2 of GP129 on the negative strand, they did not
impact the GP129 ORF coding sequences.
VirusesN13R10 and r129were reconstituted by cotransfection of BAC
DNAsN13R10 orN13R10-r129, respectively, with plasmid pCre followed
by limiting dilution isolation of viruses negative for green fluorescent
protein expression (BAC origin-excised) as described previously (21). Vi-
rion DNA from virus r129 was PCR amplified using primers GP129-out
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FWandGP129-outRV, and the productwas Sanger sequenced to confirm
the absence of the 4-bp mutation.
For analysis of genome stability following serial passage of r129 virus
in cell culture, a viral isolate from a positive blood culture (P0) from a
cyclophosphamide-treated animal (described below) was subjected to se-
rial passage in GPL cells on a monthly basis for 11 consecutive passages.
PCR employed the primers originally described by Nozawa (10): primer
1.6 Kb P1 (GTAGGTACCCGCAGGTTTGC) and primer 1.6 Kb P2 (TT
GATCACGGACGACGATAC). PCR products were subjected to agarose
gel electrophoresis to examine for full-length and deletion variants, as
described by Nozawa (10), using DNA extracted from serially passaged
ATCC (22122 strain) virus as a comparator. PCR amplification products
were sequenced by standard Sanger sequencing. Real-time quantitative
PCR (qPCR) was also performed on DNA extracted from each passage
using previously described primers for the GP83 gene (8) and a primer-
probe set spanning a 184-bp region corresponding to the GP133 gene
(positions 206914 through 207097 as annotated inGenBank accession no.
KM384022). These primers were forward primer 5=-TATTCCGTCAATG
CTCACCA-3=, reverse primer 5=-CCAACTGGCCCACTACATCT-3=
and probe CFR610-TCGAGATCATTGGACAGCTG-BHQ2. (“BHQ2” is
black hole quencher 2.) The PCR was performed in a 25 l mixture using
LightCycler 480 ProbesMaster fromRoche, as well as 0.4Mprimers, 0.1
M probe, and 0.4 U of uracil-DNA glycosylase (UNG). PCR was per-
formed using the LightCycler 480 real-time PCR system (Roche) under
the following conditions: UNG incubation at 40°C for 10min, with initial
denaturation at 95°C for 10 min, followed by 95°C for 10 s, 56°C for 15 s,
and 72°C for 10 s for a total of 45 cycles, and then a final hold step at 40°C.
Data were analyzed with the LightCycler data analysis software (version
1.5; Roche) using standard curves generated with serial dilutions of BAC
N13R10-r129 at known concentrations.
Animal pathogenicity studies.All animal procedureswere conducted
in accordance with protocols approved by the Institutional Animal Care
and Use Committee at the University of Minnesota, Minneapolis. Out-
bred nonpregnant or timed-pregnant Hartley guinea pigs were purchased
from Elm Hill Laboratories (Chelmsford, MA). Animals were assessed as
GPCMV IgG seropositive or seronegative by enzyme-linked immunosor-
bent assay (ELISA) as previously described (22).
Viral challenge studies were performed with cyclophosphamide-
treated immunocompromised guinea pigs as previously described (23).
Three groups (n 5/group) of nonpregnant seronegative Hartley guinea
pigs were treated with 100 mg/kg cyclophosphamide by intraperitoneal
injection 1 day prior to and 7 days after viral challenge. Animals were
challenged with virus r129 or N13R10 or sham infected with phosphate-
buffered saline (PBS). Viruses were administered subcutaneously (s.c.) at
a dose of 5 107 PFU. Animal weights were monitored every 3 to 5 days,
and blood samples were obtained on days 0, 3, 7, 14, and 21 postinocula-
tion for viral load determination by qPCR. Two animals in the r129 group
becamemoribund due to extreme weight loss and were sacrificed on days
21 and 24. The remaining animalswere sacrificed onday 28. Liver, salivary
gland, lung, and spleen samples were collected for viral load determina-
tion by qPCR.
Pregnancy status was monitored by palpation. For pregnancy/chal-
lenge studies seronegative (n  18) or seropositive (n  6) timed-preg-
nant animals were challenged s.c. at approximately 35 days of gestation
with either 1 105 PFUof SG-GCMVor 5 107, 5 106, or 5 105 PFU
of r129 virus. This dose rangewas chosen primarily to identify the optimal
dose of r129 virus required for inducing pup mortality. Maternal bleeds
were obtained 7 days postchallenge for qPCR. Pregnancy outcomes were
monitored, and pup tissues were immediately harvested from stillborn
pups at delivery or within 72 h postdelivery for live-born pups.
Western blot assays.Western blot assays were conducted using stan-
dard protocols, with virus particles purified as described previously (15).
Virus particles from N13R10, r129, and SG virus (passaged once in GPL
cells; 10 g per lane) were separated by SDS-PAGE, transferred to nitro-
cellulose membranes, and probed using antibodies specific for GPCMV
proteins (Fig. 2A). GPCMV glycoprotein B (gB) was detected using mu-
rine monoclonal anti-gB antibodies IE3-21 (3) or 29.29. Rabbit and
guinea pig antisera specific to GP129, GP131, and GP133 are described
elsewhere (15). The guinea pig antiserum to GP129 was raised against a
glutathione S-transferase (GST) fusion protein, includingGP129 residues
Asn146 through Lys179 of the GP129ORF, andwas therefore not predicted
to react with any putative truncated forms of GP129 corresponding to the
first 101 codons of the ORF that might be expressed in the context of the
4-bp deletion mutation. A rabbit antipeptide serum specific for GPCMV
gH was generated by immunization with the synthetic peptide SGSGRR
DYSEARIAEI conjugated to keyhole limpet hemocyanin (Pacific Immu-
nology). The GP133 antiserum was used at a 1:100 dilution; antiserum to
GP129, GP131, or gH, was used at a 1:200 dilution. Horseradish peroxi-
dase (HRP)-conjugated anti-rabbit IgG secondary antibody (Cell Signal-
ing Technologies) was used at a 1:20,000 dilution; HRP-conjugated anti-
mouse and anti-guinea pig IgG (Cell Signaling Technologies) antibodies
were used at 1:5,000 dilutions. Western blots were developed using the
ECL Prime enhanced chemiluminescence Western blotting reagent (GE
Biosciences), and autoradiography was carried out according to the man-
ufacturer’s specifications.
Real-time qPCR analysis. Viral loads were determined by qPCR as
described previously (8, 24). Briefly, DNA was extracted from either 100
l citrated blood (MagNA Pure LC DNA isolation kit I; Roche) or from
tissues obtained at necropsy using 0.1 g of homogenized frozen samples of
liver, lung, or spleen (MagNA Pure LC DNA isolation kit II; Roche).
Amplification primers GP83TM_F1 (CGTCCTCCTGTCGGTCAAAC)
and GP83TM_R1 (CTCCGCCTTGAACACCTGAA) were used at a final
concentration of 0.4 M, while the GP83 hydrolysis probe (6-carboxyflu
orescein [FAM]-CGCCTGCATGACTCACGTCGA-BHQ1) was used at
0.1 M. PCR was performed using the LightCycler 480 real-time PCR
system (Roche) under the following conditions: 40°C for 10 s and 95°C for
15min, followed by 45 amplification cycles of 95°C for 10 s, 56°C for 15 s,
and 72°C for 10 s. Data were analyzed with the LightCycler data analysis
software (version 1.5; Roche) using standard curves generated from
known copy numbers of modified plasmid pCR 2.1 containing GP83 se-
quences (24). DNAemia was expressed as the total number of genome
copies per milliliter of blood. The limit of detection was approximately
200 copies/ml. For the purpose of statistical comparisons, a level of 100
copies/ml was assigned to negative samples. Tissue viral loads were ex-
pressed as genome copies per milligram of tissue. The limit of detection
was approximately 2 genome copies/mg tissue. For the purpose of statis-
tical comparisons, a value of 1 copy/mg was assigned to negative samples.
Histological and IFL analyses.Liver sampleswere harvested from two
r129-infected guinea pigs (21 and 24 days postchallenge) and one sham-
infected guinea pig (day 28 postchallenge). Tissue samples were washed in
ice-cold PBS, fixed with fresh 4% paraformaldehyde (PFA), and then
cryoembedded in Tissue-Tek OCT compound (Sakura Finetek) and fro-
zen in liquid nitrogen. Sections of 7 m were air-dried and fixed in 4%
PFA, stained with hematoxylin and eosin, mounted using Permount
(Fisher), and examined by light microscopy. For immunofluorescence
(IFL), sections were permeabilized with 0.1% Triton X-100 in PBS for 30
min at room temperature, washed three times in PBS, and then incubated
in blocking buffer (10% normal goat serum) for 1 h at room temperature.
Following overnight incubation at 4°Cwithmouse anti-GPCMVgB 29.29
monoclonal antibody (1:500), slides were washed in 0.3% Tween 20 and
incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG second-
ary antibody (1:500 [Molecular Probes]) followed by staining of cellular
nuclei with DAPI (4=,6-diamidino-2-phenylindole) Fluoromount-G
(Electron Microscopy Sciences, PA). For immunoenzymatic detection
methods, endogenous peroxidase activity was blocked by incubating
slides in 3% H2O2 in tap water. Slides were blocked in 2.5% horse serum
for 30 min followed by incubation at 4°C with an anti-guinea pig GP83
rabbit monoclonal antibody (1:1,000). After washing in 0.3% Tween 20,
slides were incubated for 1 h at room temperature with ImmPRESS re-
agent anti-rabbit Ig (Vector Laboratories, CA) and washed and incubated
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in ImmPACT diaminobenzidine (DAB) peroxidase (HRP) substrate so-
lution (Vector Laboratories, CA). The slides (see Fig. 7) were counter-
stained with hematoxylin QS nuclear stain according to the manufactur-
er’s instructions (Vector Laboratories).
Statistical analyses. GraphPad Prism (version 6.0) was used for sta-
tistical analyses. Parametric data included viral load measurements in
blood and pup tissue and weight loss in cyclophosphamide challenge
studies. These were compared using 2-way analysis of variance (ANOVA)
followed by posttest Bonferroni multiple comparison.
RESULTS
Restoration of wild-type GP129-GP130 sequences in BAC
N13R10. The HCMV PC is composed of glycoproteins H and L
(gH and gL, respectively) complexed with UL128, UL130, and
UL131A proteins. Orthologous subunits of these HCMVUL pro-
teins form the GPCMV PC, consisting of gH, gL, GP129, GP131,
and GP133, respectively (15–18). As shown in Fig. 1A, the GP129
gene, which encodes the GP129 subunit, is comprised of three
exons on the complementary (leftward direction) strand. Adja-
cent and also on the complementary strand are genes GP131 and
GP133, which encode the GP131 and GP133 proteins, respec-
tively. Overlapping GP129 on the opposite strand is an uncharac-
terized hypothetical ORF, GP130. As shown in Fig. 1A, a 4-bp
deletion in N13R10 frameshifts GP130 near the 5= end and also
frameshifts GP129 near the 5= end of exon 3 (14), thus disrupting
both predicted proteins.
To ascertain if the 4-bp deletion contributes to attenuation of
N13R10 virus, markerless gene transfer in E. coli was used to re-
place the mutant GP129 and GP130 sequences in N13R10 with
wild-type sequences from SG virus tomake virus r129 (for details,
see Materials and Methods). Sequencing of r129 DNA confirmed
repair of the 4-bp deletion such that GP129 and GP130 reading
frameswere restored. These geneticmanipulations resulted in two
spontaneous mutations that produced R93Q and P97S substitu-
tions in the predicted amino acid sequence of GP130 but did not
alter the predictedGP129 amino acid sequence, because both sub-
stitutions fell within the intron between exons 1 and 2 of GP129.
In sequencing of neighboringORFs, an incidental amino acid sub-
stitution was also noted in GP131, H131N. These sequences were
stable following serial passage of virus through 10 passages in
cell culture (described below). In a growth curve experiment start-
ing with amultiplicity of infection (MOI) of 0.01, r129 replication
in GPL fibroblasts was similar to that of parental virus N13R10
with respect to both kinetics and yield of infectious virus produc-
tion (Fig. 1B). Thus, repair of the frameshift mutation in the
GP129 sequence did not significantly impair or enhance GPCMV
replication in cultured fibroblasts.
Repair of the 4-bp deletion in GP129 and GP130 restores vi-
rion incorporation of GP129, GP131, and GP133 proteins. In
HCMV, mutations that disrupt expression of any of the three PC
subunits (UL128, UL130, or UL131A) result in the generation of a
virus that fails to incorporate the other two subunits into virions
(25). To determine if a similar all-or-none phenomenon occurs in
GPCMV, r129 and N13R10 virion particles were purified and an-
alyzed byWestern immunoblotting using monoclonal antibodies
FIG 1 Structure and in vitro growth properties of virus r129. (A) HindIII restriction map of the GPCMV genome showing the location of BAC cloning vector
sequences in N13R10. TheGP129-to-GP133 locus is expanded below. Genes that encode PC subunits are shown in green, while ORFs encoding uncharacterized
hypothetical proteins are in gray. The location of a 4-bp deletion present in BAC N13R10 (13, 14, 17) that impacts both GP129 exon 3 and GP130 is shown. (B)
GPL cells were infected with virus r129 or parental virus N13R10 at anMOI of 0.01, and virus titers in the culture supernatants were determined through 17 days
postinfection. The dashed line indicates the limit of detection.
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to GPCMV gB or rabbit and guinea pig antisera specific to the gH,
GP129, GP131, or GP133 proteins.While similar gB and gH levels
indicated that the two virion preparations contained equivalent
amounts of virions, the GP129, GP131, and GP133 proteins were
present in r129 virions but undetectable in N13R10 virions (Fig.
2A). These data indicated that repair of r129 resulted in localiza-
tion of the GP129, GP131, and GP133 proteins to the purified
virions. As a control, the same analyses were performed on SG-
derived virions, and these experiments confirmed that compara-
bly sized proteins were produced (Fig. 2B). Preimmune sera from
rabbits and guinea pigs used for generation of antibodies to PC
components were not reactive to virion proteins fromN13R10 or
r129 virions (data not shown) or with SG virus-derived virions
(Fig. 2B, preimmune). These data support the conclusion that the
failure of N13R10 to express the GP129 subunit is due to the 4-bp
deletion, which in turn results in failure to incorporate the GP131
or GP133 subunits into N13R10 virions. Repair of the deletion in
r129 restored GP129 expression, and this in turn permitted as-
sembly and incorporation of the full PC into r129-derived virions.
Repair of the 4-bp deletion in GP129 and GP130 results in
enhanced virulence in immunocompromised guinea pigs. To
address whether repair of the 4-bp deletion restored pathogenic
potential to BAC-derived GPCMV, a challenge study in cyclo-
phosphamide-immunosuppressed animals was performed. Three
groups of five animals were treated with cyclophosphamide on
days 0 and 8 (Fig. 3). Animals were either sham inoculated s.c.
with PBS or inoculated with matching 5  107-PFU doses of vi-
rusesN13R10 or r129. Animalweightsweremonitored, and blood
samples were collected periodically until animals were sacrificed
on day 28. All animals in the sham- and N13R10-infected groups
survived the 28-day study and exhibited maximal mean weight
losses of 5.6 and 6.2%, respectively (Fig. 3). In contrast, the max-
imal mean weight loss of r129-infected animals was 20.9% (P 
0.05, compared to control orN13R10 on day 21), and two animals
were sacrificed early (on days 21 and 24 postinfection) due to
moribund condition after losing 24.3 and 30.2% of body weight,
respectively (Fig. 3).
Mean viral loads in blood from days 3 to 21 were statistically
significantly higher at each time point in the r129 group compared
to the N13R10 group (Fig. 4). Animals inoculated with r129 also
had a longer duration of viremia (4/5 animals positive at day 21,
versus 0/5 animals in the N13R10 group at day 21). No animals
FIG 2 Virion incorporation of GP129, GP131, or GP133. (A) Virion particles were purified from supernatants of N13R10- or r129-infected GPL cultures,
separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed using antibodies specific for the indicated GPCMV proteins as indicated in the
text. The locations of protein molecular weight standards are indicated. (B) Virion particles were purified from infected GPL monolayers inoculated with
SG-adaptedGPCMV (passaged once in cell culture), separated by SDS-PAGE, and probedwith the indicated pre- and postimmune sera. The locations of protein
molecular mass standards (kDa) are indicated.
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from the sham-inoculated (PBS) group had viral loads above the
threshold of detection at any time point (data not shown).
On day 28, all surviving animals were euthanized and organs
harvested for PCR-based viral load assessment. Significant differ-
ences in viral load were noted between groups (Table 1). On av-
erage, animals infected with r129 exhibited levels of viral DNA
1.1 106-, 1.1 105-, 1.5 106-, and 2.0 104-fold higher than
those of N13R10-infected animals in liver, lung, spleen, and sali-
vary gland, respectively.
Virus r129elicitsmaternal viremia, congenital infection, and
pup mortality in immunocompetent pregnant guinea pigs.
Pregnancy/challenge studies were conducted to examine the abil-
ity of virus r129 to produce disease in pregnant guinea pigs, in-
cluding maternal viremia, pup mortality, and vertical transmis-
sion. Timed-pregnant animals were divided into four groups (n
6 animals/group). In group 1, both GPCMV-seropositive (n 3)
and GPCMV-seronegative (n 3) animals were challenged in the
early third trimester with 1 105 PFU of SG-GPCMV. In groups
2 and 3, all animals were GPCMV seronegative (n 6/group) and
were inoculated with either 5 105 or 5 106 PFU of r129 virus,
respectively. In group 4, GPCMV-seropositive (n 3) and -sero-
negative (n 3) dams were inoculated with 5 107 PFU of r129
virus.
Analyses of the outcomes in these groups (Table 2) demon-
strated that r129 virus was capable, in a dose-dependent fashion,
of producing maternal DNAemia and congenital transmission,
with attendant pup mortality. In seronegative dams challenged
with SG-GCMV, pup mortality was 8/12 (67%), and congenital
GPCMVtransmission (as gauged by any positive PCR inpup liver,
lung, or spleen) occurred in 10/12 pups (83%). In seropositive
dams challenged with SG-GPCMV, there was no pup mortality,
but interestingly, 6/9 pups (67%) had congenital infection, al-
though viral loads were low (Table 2). In seronegative dams (n
3) challenged with r129 at the highest dose (5  107 PFU), pup
mortality was 13/13 (100%), and congenital transmission oc-
curred in all 13 pups (100% transmission rate). In seropositive
dams challenged with this dose, mortality was 3/14 (21%), and
congenital infection occurred in 7/14 pups (50%). In seronegative
dams challenged with r129 at a dose of 5 106, pupmortality was
7/25 (28%), and transmission occurred in 24/25 pups (96%). In
contrast, no pup mortality (0/20) was observed when dams were
challenged with 5 105 PFU, although 16/20 pups (80%) none-
theless had evidence of congenital infection (Table 2).
The magnitudes of maternal DNAemia at day 7 were also sim-
ilar when comparing challenge with SG-GPCMV and r129 virus.
For SG-GPCMV-inoculated seronegative dams, the mean day 7
viral load was (5.1  2.2)  106 genomes/ml; for the r129 5 
107-PFU seronegative group, it was (5.5  1.5)  106 genomes/
ml; for the r129 5  106-PFU seronegative group, it was (3.7 
1.1) 106 genomes/ml; and for the r129 5 105-PFU seronega-
FIG 3 Weight loss following inoculation of cyclophosphamide-treated guinea pigs. Adult seronegative guinea pigs were treated with cyclophosphamide on days
0 and 8 relative to viral challenge on day 1. Groups of 5 animals were either sham inoculated s.c. with PBS or inoculated withmatched 5 107-PFU doses of virus
N13R10 or r129.Mean percentages of changes in weight SEM are plotted over time.Weight losses in the r129-inoculated group were significantly greater than
those in the PBS- or N13R10-inoculated groups at all time points (P 0.05). Arrowheads show timing of cyclophosphamide inoculation (days 0 and 8) relative
to viral infection.
FIG 4 Systemic viral loads following inoculation of cyclophosphamide-
treated guinea pigs. Viral loads were determined by qPCR of blood samples
collected on days 0, 3, 7, 14, 21, and 28 from experimentally inoculated, cyclo-
phosphamide-treated animals described in the legend to Fig. 3. The data
shown are mean log10 genome equivalents SEM per milliliter of total blood.
Samples with undetectable levels of DNAwere assigned a value of 2 log10 based
on the limit of PCR detection for purposes of statistical comparisons (24). *,
P 0.02, and **, P 0.0001, r129 versusN13R10; ***, P 0.0001, r129 versus
control.
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tive group, it was (1.3 0.6) 106 genomes/ml (P not significant
[NS] across all seronegative dam groups, Kruskal-Wallis with
Dunn’s multiple comparisons).
In addition tomortality differences across groups, pupweights
at birth varied in a dose-dependent fashion following inoculation
of pregnant animals with SG or r129 virus (Fig. 5). Seronegative
dams challenged with SG virus (1 105 PFU) gave birth to pups
with a birth weight of 52.3 of 6.23 g (mean standard error of
the mean [SEM]). Seronegative dams challenged with 5  107
PFUof r129 virus delivered pupswith a birthweight of 49.4 2.69
g. These weights were significantly lower than those of pups born
to seronegative dams challengedwith r129 at doses of 5 106 PFU
(85.7 3.57 g) or 5 105 PFU (101 3.9 g) (Fig. 5A). Seropos-
itive dams challengedwith SG virus gave birth to pups with a birth
weight of 96.8  3.96 g (mean  SEM). Seropositive dams chal-
lenged with 5  107 PFU of r129 virus delivered pups with a
significantly lower birth weight of 70.5  5.76 g (Fig. 5B). As a
control, a parallel study of healthy, noninfected dams ongoing in
our vivarium during the same period produced 21 pups (n  7
dams) with a birth weight of 95.7 16.9 g.
Virus r129 exhibits genome stability upon serial passage in
cell culture. Studies of the 22122 strain of GPCMV from ATCC
demonstrated that the ATCC stock is a mixture of a full-length
genome variant and a variant with a 1.6-kb deletion in the region
encoding PC subunits GP129, GP131, and GP133 (10). Subse-
quent work suggested that even a plaque-purified full-length vari-
ant demonstrated genome instability in this region, insofar as se-
rial passage of virus purified from a single plaque led to eventual
identification of variant viruses with deletion of this 1.6-kb patho-
genicity locus (18). To examine the genome stability of virus r129,
serial tissue culture passages through 11 passages were undertaken
on a monthly basis by subculture on GPL cells, starting with an
isolate obtained from a positive blood viral culture from an r129-
challenged animal (P0). Compared to ATCC stock virus (strain
22122), which after a limited number of passages in fibroblasts
demonstrated the predicted shift toward predominately the
1.6-kb deletion variant (indicated by the 348-bp PCR product),
the genome of virus r129 was stable, as indicated by the exclusive
presence of the 1,994-bp PCR product in Fig. 6A, upper panel. A
parallel study of SG virus (maintained for30 years exclusively in
vivo through serial passage of SG homogenates in strain 2 guinea
pigs [20]) demonstrated similar high levels of stability following
serial viral passage in fibroblasts (Fig. 6A, lower panel). No evi-
dence of the 1.6-kb deletion in either r129 or SG virus was ob-
served after continued additional serial passage in fibroblasts out
to passage 16 (data not shown).
Although PCR-based comparisons suggested at the level of gel
electrophoresis that the r129 virus did not undergo deletions in
the region of the viral genome previously identified as absent in a
subpopulation of GPCMV variants in ATCC viral stock (10), it
was noted that this level of analysis might fail to detect any muta-
tions that included loss of the primer binding sites used to amplify
the 1,994-nucleotide (nt) region. Thus, if the r129 virus had a
larger deletion, including sequences on either side of the 1,994-nt
region, then the PCR would potentially amplify sequence only
from the small percentage of wild-type genomes present after se-
rial passage, making viral stock appear wild-type when in fact a
deletionmutant was the major form present. To address this con-
cern, we performed additional quantitative PCR on DNA ex-
tracted from each passage (P0 to P10) of serially passaged r129
TABLE 1 Tissue viral loads in cyclophosphamide-treated guinea pigs 27 days after s.c. inoculation with 5 107 PFU N13R10 or r129
Challenge virus
Viral load (genome copies/mg) ina:
Liver Lung Spleen Salivary gland
N13R10 26 11.8 16 15 84.7 3.7 99.4 88.9
r129 (1.3 2.5) 107** (1.7 1.7) 106* (1.2 1.2) 107** (6.6 1.3) 105
a Expressed as genome copies per milligram of tissue SEM. The limit of detection was	2 genome copies/mg. For the purpose of statistical comparisons, negative samples were
assigned a value of 1 copy/mg. *, P0.01 versus N13R10; **, P0.001 versus N13R10.
TABLE 2 Pup mortality and maternal and pup viral loads following challenge during pregnancy with SG or r129 virus
Challenge virus
dose (PFU)a
Dams Pups
Dose group (n)b
Viral load
(106 genome copies/ml)c
Infection, no.
infected/total (%)
Mortality, no. of stillborn
pups/total deliveries (%)
Viral load (genome copies/mg) ind:
Liver Lung Spleen
SG virus
1 105 Seronegative (3) 5.1 2.2 10/12 (83) 8/12 (67) 240 107 22 6.4 793 429
Seropositive (3) 1.8 1.8 6/9 (67) 0/9 (0) 14.3 6 150 88.5 32.5 11.4
r129
5 105 Seronegative (6) 1.3 0.6 16/20 (80) 0/20 (0) 6.7 1.9 47.8 17.5 52.1 20.1
5 106 Seronegative (6) 3.7 1.1 24/25 (96) 7/25 (28) 117 70.7 45.2 14.6 212 128
5 107 Seronegative (3) 5.5 1.5 13/13 (100) 13/13 (100) 23,129 8,820 484 196 66,788 27,984
Seropositive (3) 0.7 0.7 7/14 (50) 3/14 (21) 30.8 25.6 51.3 39.9 110 76.7
a SG, pathogenic salivary gland extract; r129, produced in cell culture.
b GPCMV seronegative or seropositive.
c Expressed as 106 genome copies/ml of blood on day 7 postchallenge.
d Expressed as genome copies per milligram of tissue at delivery. The limit of detection was approximately 2 genome copies/mg tissue. For the purpose of statistical comparisons,
negative samples were assigned a value of 1 copy/mg. For the purpose of ascertaining congenital infection rates, any pup that had qPCR values falling below the limit of detection of
the assay was considered uninfected.
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virus, using both previously described primers specific for the
GP83 gene (8) and a primer-probe set spanning a 184-nt region
corresponding to the GP133 gene, a gene that would be deleted if
the 1.6-kb deletion (or a larger deletion corresponding to se-
quences flanking this region) were selected for in cell culture. Par-
allel comparisonsweremadewith serially passagedATCC (22122)
stock. Stability of this region of the genome on serial passage
would be predicted to result in a ratio of GP133 to GP83 of	1 by
qPCR, whereas a complete deletion would result in a ratio ap-
proaching 0. This analysis demonstrated that the molar ratio of
these two target sequences was	1.0 after 10 passages in cell cul-
ture for r129 virus. In contrast, ATCC virus (22122 strain), dem-
onstrated a decrease in the ratio of full-length to deletion variant
to approximately 50% for P2 and a decrease to 18% at P3. By
passage 10, the ratio of full-length to deletion variant for ATCC
virus was	6% (Fig. 6B). These results confirmed the stability of
this genome region in r129 virus.
As a final confirmation of genome stability in this region, we
sequenced the entire 1,994-bp PCR product, which spans all three
PC ORFs contained in this region (GP129, GP131, and GP133)
and also includes 38 bp 3= of the GP129 stop codon and 189 bp 5=
of theGP133 start codon. Sequencewas obtained fromP0material
(obtained from a positive viral blood culture from an experimen-
tally challenged animal) and P10 material. These sequences were
identical (data not shown). An incidental amino acid substitution
was noted in the GP131 ORF, H131N. Notably, this amino acid
substitution fell outside the peptide region used to make the anti-
GP131 antibody used for Western blot analyses.
Virus r129 exhibits end organ pathology in experimentally
infected animals. To assess the ability of r129 virus to cause end
organ pathology and to examine whether infection of guinea pigs
with the rescued virus was associatedwith an alteration in host cell
tropism, histological and immunohistochemical analyses of liver
tissue recovered from cyclophosphamide-treated animals (inocu-
lated with 5 107 PFU of N13R10 or r129 virus) were performed.
In r129-inoculated animals, cytomegalic cells and inflammatory
cell infiltrates were observed, and GPCMV-infected hepatocytes
were detected using immunohistochemical staining for expres-
sion ofGP83 or gB proteins (Fig. 7). No histopathology or positive
antigen staining was detected in liver tissue harvested from ani-
mals challengedwith the parental virusN13R10 (data not shown).
DISCUSSION
Viral attenuation through cell culture passage has been a valuable
tool for identification of viral genes important for pathogenesis
and for development of live attenuated vaccines. The first HCMV
vaccine candidates were comprised of live strain Towne or AD169
viruses produced following extensive serial passage on cultured
fibroblasts (26–29).When experimentally administered to human
volunteers, these vaccines were highly attenuated. In contrast, 10
PFU of low-passage-number Toledo strain virus was pathogenic
in humans (30). Later passages of AD169 and Toledo were found
to have substantial deletions and inversions impacting a number
of genes in the UL/b= region (31, 32). Unfortunately, these muta-
tions cannot be clearly linked to attenuation or virulence as it is
possible that somemutations occurred at latter passage and stocks
that were used in humans are no longer available for study. How-
ever, analysis of the viruses in an original Towne vaccine vial re-
vealed an 	50/50 mixture of two genome variants. The Towne-
VarS genome had a large deletion of UL/b= sequences similar to
that of AD169, while TowneVarL retained the complete comple-
ment of known HCMVORFs (31, 33, 34). Sequencing of Towne-
VarL revealed that only five annotated ORFs contain mutations
that abrogate protein expression: UL13, UL1, UL40, UL130, and
US1 (35). Thus, it is reasonable to conclude that one or more of
these five mutations contribute significantly to attenuation of the
Towne vaccine.
Of particular interest is the mutation in UL130, as it disrupts
formation of a functional PC. In HCMV the PC is comprised of
gH, gL, UL128, UL130, and UL131A, the analogs of GPCMV gH,
gL, GP129, GP131, and GP133, respectively (15–18, 25, 36). The
HCMV PC is required for efficient entry into epithelial cells, endo-
thelial cells, monocytes, and monocyte-derived dendritic cells, but
UL128, UL130, and UL131A are entirely dispensable for fibroblast
entry (36, 37). Thus, by rendering Towne viruses incapable of enter-
ing and replicating in these cell types, theUL130mutationmay con-
tribute significantly to attenuation of the Towne vaccine in vivo.
Live attenuated vaccines have been studied in the guinea pig
model. Like Towne, GPCMV strain variants used as vaccines in
early studies were attenuated by serial passage in fibroblasts (38),
although the precise details of genomic deletions or mutations
were not explored. Later work showed that, likeHCMV, fibroblast
passage of GPCMV results in mutations that remove or disrupt
GPCMV genes that encode PC subunits GP129, GP131, or GP133
(16–18). In order to develop a genetic system to study GPCMV, we
constructedN13R10,a full-lengthBACcloneof theGPCMVgenome
derived from a fibroblast-adapted stock (9). Virus derived from
N13R10 was highly attenuated in animals compared to virulent SG-
FIG 5 Pup weights following inoculation of pregnant guinea pigs with SG or
r129 virus. Pregnant dams were inoculated s.c. with the indicated doses of SG
or r129 virus. Pup weights and viability were determined at delivery. Data
shown are for pups born to seronegative challenged dams (A) and for seropos-
itive challenged dams (B). A dose-dependent impact on pupweights andmor-
tality is notedwith r129 virus in seronegative dams (A). Statistical comparisons
were performed using Kruskal-Wallis with Dunn’s multiple comparison test.
Significant differences among groups are as indicated by P values. Blue, live-
born pups; orange, stillborn pups.
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passaged virus stocks (11, 12). To test for genetic differences that
might contribute to attenuation of N13R10 virus, we sequenced the
N13R10 BAC (14) and also sequenced the SG-derived GPCMV ge-
nomeusingDNApurified directly from salivary glandhomogenates,
without any intermediate passage infibroblasts (20). Remarkably,we
found only 13 differences, and of these, only 2 impacted annotated
ORFs: a 4-bp deletion/frameshift disruptingGP129 andGP130 and a
predicted F81C amino acid substitution in GP130 that is 3= of the
4-bp deletion/frameshift.
The present study confirms that the 4-bp deletion/frameshift is
a major contributor to attenuation of N13R10. In immunocom-
promised animals, r129 virus induced a longer duration and
FIG 6 Stability of GPCMV genome of r129 virus following fibroblast tissue culture passage. (A) PCR was performed to evaluate for emergence of an	1.6-kb
deletion in the GPCMV genome following serial passage of r129 virus in GPL cells. (Upper panel) Virus isolated from blood culture of a cyclophosphamide-
treated r129-challenged guinea pig (P0)was subjected to 11 rounds of serial passage inGPLfibroblasts (P1 to P11; P0 representsDNApurified directly from index
blood culture). DNA was purified following each round of passage and subjected to PCR using primers originally described by Nozawa et al. (15). As controls,
DNAwas analyzed fromATCC-derivedGPCMV(passaged in parallel [data shown for P3 andP10]) and SG-passaged viral stock (SG
 1/P0). (Lower panel) PCR
following 10 serial passages of highly SG-adapted virus. Full-length genome was exclusively found in SG-passaged virus. Positions of molecular size markers are
indicated. Arrowheads indicate positions of full-length and deletion genome variants. (B) Ratio of qPCR products following serial passage of 22122 (ATCC) and
r129 virus. Primers specific for theGP83 gene and a primer-probe set spanning a 184-bp region corresponding to theGP133 gene (mapping to the 1.6-kb-deletion
region) were used to amplify DNA extracted from each serial cell culture passage. Complete stability of the region of the genome would be predicted to result in
a ratio of GP133 to GP83 of	1 on serial passage, whereas selection of a deletion variant would result in a ratio approaching 0. This analysis demonstrated that
the molar ratio of these two target sequences (normalized to P1) was	1.0 after 10 passages in cell culture for r129 virus (gray bars), but that ATCC virus (22122
strain) virus demonstrated a decrease of the ratio of full-length to deletion variant to approximately 50% for P2, a decrease to 18% at P3, and a decrease to10%
for later passages (white bars).
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higher magnitude of viremia (Fig. 4) and also produced substan-
tially higher end organ viral loads (Table 1). Notably, r129-in-
fected animals also experienced profound weight loss (of suffi-
cient severity in two animals to necessitate euthanasia), while the
weight changes of N13R10-infected animals were no different
from those of the PBS-inoculated controls.
In the congenital infection model virus r129 was capable of
establishing maternal DNAemia and inducing pup infection and
mortality (Table 2). A dose response was evident with respect to
the magnitude of maternal DNAemia at day 7 postinoculation,
with 77% and 34% lower levels in the magnitude of viral load in
the 5  105- and 5  106-PFU challenge groups, respectively,
compared to the 5 107 challenge group. Striking differences in
pup mortality were observed, with mortality rates of 100% (13/
13), 28% (7/25), and 0% (0/20) across these three doses. These
differences suggest that even small variations in the magnitude of
maternal DNAemia can produce differences in pupmortality. Fu-
ture experiments will be required to define the threshold of ma-
ternal DNAemia associated with pup mortality using the r129 vi-
rus. There was also a clear dose response with respect to pup
weights (Fig. 5A), with statistically significantly higher pup
weights in the 5 105-PFU (P 0.0001) and 5 106-PFU (P
0.004) r129 challenge groups compared to the 5 107-PFU chal-
lenge group in GPCMV-seronegative dams.
From the data presented, however, attenuation of N13R10
cannot be rigorously attributed to loss of GP129 expression. The
4-bp deletion also introduces an in-frame stop after codon 5 of
GP130, and repair of the mutation restores the normal reading
FIG 7 End organ pathology and replication with r129 virus in guinea pigs. Animals were either infected with r129 virus (A, B, D, E, G, and I) or mock infected
(C and F) as described in Materials andMethods. Cytomegalic cells are noted (A [arrowheads]) as well as inflammatory cell infiltrates (B [arrow]). Both panels,
600magnification. Immunoperoxidase stainingwithGP83-specific rabbitmonoclonal antibody demonstrates viral antigen in r129-infected guinea pig hepatic
tissue (D and E) but not the mock-infected control (F). Immunofluorescence staining withmouse anti-guinea pig gB 29.29monoclonal antibody (G) and DAPI
counterstain (H and higher-magnification inset in panel I) confirmed GPCMV infection of hepatocytes. CMV antigen-positive cells were detected dispersed
through the tissue from animals infected with r129 virus but not in uninfected or N13R10-infected controls.
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frames of bothGP129 andGP130. Thus, attenuation could be due
to loss of GP129, loss of GP130, or cumulative effects of losing
both. One limitation of these studies is that both the N13R10 and
r129 viruses contain missense mutations in GP130. The missense
mutation in N13R10 is irrelevant, as in N13R10 it is 3= of the
frameshift, and in r129 it was successfully repaired.However, dur-
ing BAC genetic manipulation, additional mutations occurred in
GP130. Consequently, while correction of the frameshift in r129 is
predicted to restore expression of a fully wild-type GP129 protein,
the predicted GP130 protein contains two amino acid substitu-
tions, R93Q and P97S. It should be noted, however, that there is
no evidence to date to indicate that GP130 encodes a functional
protein. The predicted 15-kDa 130-amino-acid protein has no
homology to any known or predicted proteins in the database.
Although an unspliced GP130-specific transcript was detected
in infected cells by reverse transcriptase PCR in previous stud-
ies, no transcript has been noted by Northern blotting (17).
While the GP130ORF is conserved in the related CIDMTR strain
of GPCMV (39), the amino acid homology between predicted
GP130 proteins is limited to the region of overlap with GP129 on
the negative strand, but is highly divergent between the two strains
downstream of codon Pro80, suggesting that partial conservation
of GP130 likely derives from selective pressure directed against
GP129. Another substitution was noted in a flanking ORF, insofar
as sequence analyses of a 1,994-nt region (spanning the region
fromGP129 toGP133) following 1 round of passage in guinea pigs
and10 rounds of passage in cell culture identified one additional
incidental amino acid substitution (H131N) in GP131. The
1,994-bp region was otherwise highly stable, and identical se-
quence in this region was noted following 10 rounds of virus
passage in cell culture. Further experiments will be required to
evaluate whether a bona fide GP130 protein exists in GPCMV-
infected cells and to investigate any potential role for GP130 and
GP131missense mutations in the pathogenesis of r129 virus. Ad-
ditional analyses will also be required to ensure that other point
mutations and/or small deletions are not present in other regions
of the r129 viral genome. The recent isolation of viralmutants that
selectively disrupt GP129 or GP130 (without impacting the other
[unpublished data]) should serve to firmly establish the relative
contributions of each ORF to viral pathogenesis.
While the composition of the GPCMV PC is similar to that of
the HCMV PC, it is not yet clear that it serves an equivalent func-
tion. Progress toward characterizing the role of the GPCMVPC in
epithelial or endothelial tropism has been frustrated by a lack of
established guinea pig epithelial or endothelial cell lines that sup-
port GPCMV replication. Using primary cells, Yamada et al.
found that the GPCMV PC is required for infection of monocytes
and macrophages (16), which is consistent with data that HCMV
infection of monocytes is PC dependent (40). However, using
primary endothelial cells, Auerbach et al. did not observe an en-
dothelial cell-specific defect for a PC-negative mutant virus, but
rather found that deletion of PC subunit genes caused an equiva-
lent reduction in entry efficiency for both endothelial and fibro-
blast cells (18). Thus, although further studies are needed, current
evidence suggests that GPCMVandHCMVPCsmay have distinct
as well as overlapping functions.
While repair of the frameshift mutation in the GP129-GP130
locus greatly enhanced the virulence of r129 compared to
N13R10, r129 was still less virulent than SG virus. An 	15-fold-
higher challenge dose of r129 (5 106 PFU) was needed tomatch
levels of transmission, pupmortality, or pup viral loads elicited by
the standard pathogenic SG virus challenge (1  105 PFU). Re-
maining genetic differences could contribute to this reduced vir-
ulence. As noted above, r129 encodes a hypothetical GP130 pro-
tein containing two amino acid substitutions and aGP131 protein
with a single amino acid change, and while the other 11 sequence
differences noted upon comparison of N13R10 and SG virus do
not lie within currently annotated ORFs, some could impact un-
annotated ORFs that encode authentic proteins, while others
might impact regulatory sequences or influence posttranscrip-
tional events such as splicing or mRNA stability. In addition, ex-
cision of the BAC origin leaves a residual 35-bp loxP site in r129
that disrupts an unannotatedORF that encodes a 136-amino-acid
hypothetical protein that has no homology to any known or pre-
dicted proteins in the database. It is possible that disruption of this
ORF contributes to reduced virulence of r129 relative to SG virus.
It is also likely that epigenetic factors unique to SG virus (pro-
duced in salivary gland) and absent from r129 virus (produced in
cell culture) account, at least in part, for the greater virulence of SG
virus, although the precise biological basis for this effect is poorly
understood. This hypothesis is supported by observations that
attenuation of murine cytomegalovirus (MCMV) occurs within
one passage in cell culture but is reversed by one passage in vivo
(41). Thus, it is possible that the protein compositions and conse-
quently the tropisms of virions produced in salivary gland epithe-
lial cells in vivomay differ from those produced in cultured fibro-
blasts. Another study suggested that the increased virulence of
MCMV SG virus in vivomight be related to the fact that SG virus
is produced in epithelial cells, whereas virus generated in other
compartments in the infected mouse, including visceral organs,
may predominately be produced following replication in fibro-
blasts (42). Other studies have suggested that the fact that T cell
immunity is limited in the salivary gland allows CMV to exploit
the mucosal microenvironment to replicate more effectively (43).
Evidence fromHCMV suggests that viruses produced in different
cell types can differ in their phenotypes, supporting this hypoth-
esis (44, 45). Further studies will be required to elucidate the
mechanism(s) responsible for the increased virulence of SG-pas-
saged GPCMV.
Notably, we observed a high degree of genome stability of the
r129 virus, compared to the ATCC (22122) strain. Serial tissue
culture passage through 11 passages, starting with an isolate from
a positive blood viral culture from an r129-challenged animal
(P0), indicated no evidence of the deletion of the 1.6-kb region
that was observed in a subpopulation ofGPCMVvariants that was
identified in studies of the ATCC strain by PCR analysis (10).
Compared to ATCC stock virus, which after a limited number of
passages in fibroblasts demonstrated the predicted shift toward
predominately the 1.6-kb-deletion variant (indicated by the
348-nt PCR product in Fig. 6A), PCR of the genome of virus r129
indicated the exclusive presence of the 1,994-nt PCR product cor-
responding to a full-length, wild-type genome configuration (Fig.
6A). To exclude the possibility of an adventitious deletion up-
stream of the primers used for PCR, a qPCR comparison of the
relative ratio of GP83 (an essential gene) signal to GP133 signal
was performed. This indicated a stable ratio for r129 virus but the
predicted decrease in the ratio of GP83 to GP133 signal in serially
passaged virus (Fig. 6B).
Although r129 virus is not as virulent as SG virus, it is impor-
tant to note that a 5  106-PFU challenge with r129 viral stock
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produced in cell culture is sufficient to elicit transmission and fetal
disease similar to the standard SG challenge dose used in this
model. As r129 culture supernatants can reach 108 PFU/ml, rou-
tine challenge with 5  106 PFU is readily achievable. The r129
virus was also demonstrated to produce immunohistochemically
demonstrable infection of epithelial cells (hepatocytes) in chal-
lenged animals (Fig. 7). It was of further interest that reinfection of
immune dams was able, in some instances, to lead to transplacen-
tal transmission, fetal infection, and fetal loss. Importantly, be-
cause cell culture-produced r129 is pathogenic and is derived
from a BAC clone that can be genetically manipulated in E. coli,
the N13R10-r129 BAC provides a platform to explore the genetic
basis of viral pathogenesis in this important animal model of con-
genital infection.
Finally, extension of these observations in GPCMV to HCMV
may shed light on understanding the mechanism(s) of attenua-
tion of Towne vaccine. By analogy with the impact of the GP129
mutation on GPCMV virulence, it seems likely that the mutation
in UL130 contributes significantly to the safety of the Towne vac-
cine. It is ironic that the same mutation may also diminish the
vaccine’s efficacy. People who are naturally infected with wild-
type strains of HCMV develop robust epithelial cell-specific neu-
tralizing responses that are largely mediated by antibodies di-
rected against the PC (46–52). Towne vaccination fails to induce
comparable epithelial cell neutralizing activities, presumably be-
cause theUL130mutation in theTowne strain prevents the assem-
bly of functional PCs in vivo (46, 53). A whole-virus, replication-
defective vaccine has been developed by Merck and is currently
undergoing phase 1 testing (https://clinicaltrials.gov/ct2/show
/NCT01986010?termmerck
cytomegalovirus&rank1). This
vaccine incorporates genetic modifications that allow conditional
replication in cell culture but block replication in vivo. Unlike
Towne, this virus expresses a functional PC, and despite the in-
ability to replicate, elicits robust epithelial cell-specific neutraliz-
ing responses in animals (50). While it is not yet known whether
the GPCMV PC contains analogous neutralizing epitopes, the
r129 virus nevertheless provides a platformwith which to evaluate
the role of the PC in vaccine efficacy. Further, the PC-positive r129
virus can be used in the animal model to emulate replication-
defective strategies similar to those employed by Merck or, as we
have pursued, live vaccines that are rationally attenuated through
deletion of viral immune evasion functions (11, 24). Future stud-
ies based on r129 promise to advance the guinea pig model and
make important contributions to our understanding of cytomega-
loviral pathogenesis and vaccine efficacy.
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